Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer

Abdollah, Firas; Karnes, R. Jeffrey; Suardi, Nazareno; Cozzarini, C.; Gandaglia, Giorgio; Fossati, Nicola; Vizziello, Damiano; Sun, Maxine; Karakiewicz, Pierre I.; Menon, Mani; Montorsi, Francesco; Briganti, Alberto

doi:10.1200/jco.2013.54.7893

Cited by 252 publications

(177 citation statements)

References 17 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…The results of our multivariable analysis are in agreement with the work of others, including increased PCSM with: earlier year of diagnosis [24], due to differences in follow-up or changes in treatment; more involved LNs [10]; higher grade disease [1]; and lack of adjuvant radiation in the LNpositive setting [25]. We did not find that the number of dissected LNs had an impact on outcome, consistent with prior work [26,27], although some have found an association between the number of examined LNs and outcomes in select situations [28,29].…”

Section: Discussionsupporting

confidence: 79%

Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer

et al. 2015

View full text Add to dashboard Cite

ObjectiveTo determine whether very small prostate cancers present in patients who also have lymph node (LN) metastases represent a particularly aggressive disease variant compared with larger LN-positive tumours. Patients and MethodsWe identified 37 501 patients diagnosed with prostate cancer between 1988 and 2001 treated with radical prostatectomy within the Surveillance, Epidemiology, and End Results database. The primary study variables were tumour size by largest dimension (stratified into: (i) microscopic focus only or 1 mm; (ii) 2-15 mm; (iii) 16-30 mm; (iv) >30 mm), regional LN involvement, and the corresponding interaction term. We evaluated the risk of 10-year prostate cancerspecific mortality (PCSM) using the Fine and Gray model for competing risks after controlling for race, tumour grade, T stage, receipt of radiation, number of dissected LNs, number of positive LNs, year of diagnosis, and age at diagnosis. ResultsThe median follow-up was 11.8 years. There was a significant interaction between tumour size and LN involvement (P-interaction <0.001). In the absence of LN involvement (36 561 patients), the risk of 10-year PCSM increased monotonically with increasing tumour size. Among patients with LN involvement (940), those with the smallest tumours had increased 10-year PCSM compared with patients with tumours sized 2-15 mm (24.7% vs 11.8%; adjusted hazard ratio [AHR] 2.84, 95% confidence interval [CI] 1.21-6.71; P = 0.017) or 16-30 mm (24.7% vs 15.5%; AHR 3.12, 95% CI 1.51-6.49; P = 0.002), and similar 10-year PCSM as those with tumours >30 mm (24.7% vs 24.9%; P = 0.156). ConclusionIn patients with prostate cancer with LN involvement, very small tumour size may predict for higher PCSM compared with some larger tumours, even after controlling for other prognostic variables. These tumours might be particularly aggressive, beyond what is captured by pathological assessment of tumour grade and stage.

show abstract

Section: Discussionsupporting

confidence: 79%

Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Furthermore, improving local control with pelvic radiotherapy combined with ADT appeared to be beneficial in pN1 PCa patients treated with an ePLND. Men with minimal-volume nodal disease (< 3 lymph nodes) and GS 7-10 and pT3-4 or positive margins as well as men with 3-4 positive nodes were more likely to benefit from combined ADT and RT after surgery [52].…”

Section: Pelvic Lymph Node Dissectionmentioning

confidence: 99%

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

et al. 2017

Self Cite

View full text Add to dashboard Cite

“…Согласно ре-троспективному анализу F. Abdollah и соавт. [30], опубликован-ному в 2014 г., при сравнении двух групп пациентов, получавших после радикальной простатэктомии с лимфаденэктомией и ги-стологически подтвержденной pN+ стадией только гормонотера-пию или в сочетании с адъювантной лучевой терапией, отмеча-лось увеличение общей выживаемости (75,1% против 87,6%; р<0,001) и опухолеспецифической выживаемости (86,2% против 92,4%, р<0,08) в группе с лучевой терапией. Медиана наблюдения составила 7,1 года.…”

Section: адъювантная лучевая терапия при наличии метастатического порunclassified

Radiation therapy for prostate cancer

Каприн¹,

Khmelevsky²,

Zubovskaya³

et al. 2016

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer

Cited by 252 publications

References 17 publications

Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer

Association between very small tumour size and increased cancer‐specific mortality after radical prostatectomy in lymph node‐positive prostate cancer

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

Radiation therapy for prostate cancer

Contact Info

Product

Resources

About